

SAM #	SAM Title - Journal Article
SAM72:2022-2025	Comparative Effectiveness of Extended-release Naltrexone versus Buprenorphine-naloxone for Opioid Relapse Prevention (X:BOT): a Multicentre, Open-label, Randomised Controlled Trial
SAM83:2022-2025	Evaluation of Amphetamine-Related Hospitalizations and Associated Clinical Outcomes and Costs in the United States
SAM84:2022-2025	Health, Polysubstance Use, and Criminal Justice Involvement Among Adults With Varying Levels of Opioid Use
SAM85:2022-2025	Alcohol-Related Nurse Care Management in Primary Care A Randomized Clinical Trial
SAM86:2022-2025	Prediction Model for Two-Year Risk of Opioid Overdose Among Patients Prescribed Chronic Opioid Therapy
SAM87:2022-2025	Combustible and Electronic Tobacco and Marijuana Products in Hip-Hop Music Videos, 2013-2017
SAM88:2022-2025	Contemporary Patterns of Marijuana Use and Attitudes Among High School Seniors: 2010 -2016
SAM89:2022-2025	Does Maternal Buprenorphine Dose Affect Severity or Incidence of Neonatal Abstinence Syndrome?*
SAM90:2022-2025	No Evidence of Compensatory Drug Use Risk Behavior Among Heroin Users After Receiving Take-Home Naloxone
SAM129	Broadening access to naloxone: Community predictors of standing order naloxone distribution in Massachusetts*
SAM130	Bupropion and Naltrexone in Methamphetamine Use Disorder
SAM131	Pneumonia and alcohol use disorder: Implications for treatment
SAM132	Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial
SAM133	Effect of e-Cigarettes Plus Counseling vs Counseling Alone on Smoking Cessation: A Randomized Clinical Trial
SAM134	Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study
SAM135	Reduced Emergency Department Visits and Hospitalisation with Use of an Unsanctioned Safe Consumption Site for Injection Drug Use in the United States
SAM136	Addiction is socially engineered exploitation of natural biological vulnerability
SAM137	The PEth Blood Test in the Security Environment: What it is; Why it is Important; and Interpretative Guidelines
SAM138	Systematic review and meta-analysis of epidemiology of internet addiction*
SAM139	Sexually Transmitted and Blood-borne Infections Among Patients Presenting to a Low-barrier Substance Use Disorder Medication Clinic
SAM140	Ageing and older people who use illicit opioids, cocaine or methamphetamine: a scoping review and literature map
SAM141	Precision dosing of methadone during pregnancy: A pharmacokinetics virtual clinical trials study*
SAM142	Quetiapine treatment for cannabis use disorder*
SAM143	New directions in the treatment of opioid withdrawal
SAM144	Contingency Management for Patients Receiving Medication for Opioid Use Disorder: A Systematic Review and Meta-analysis
SAM145	Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability
SAM146	Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample*
SAM147	Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls
SAM148	Cannabis Use and Stroke: Does a Risk Exist?*

SAM #	SAM Title - Journal Article
SAM149	Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use*
SAM150	Factors associated with opioid overdose during medication-assisted treatment: How can we identify individuals at risk?
SAM151	Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial
SAM152	Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial
SAM153	Alcohol use disorder and the liver
SAM154	The role of oxytocin in alcohol and drug abuse
SAM155	Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study*
SAM156	High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder
SAM157	Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: A state-level trends analysis
SAM158	Effect of initiation of medications for opioid use disorder on hospitalization outcomes for endocarditis and osteomyelitis in a large private hospital system in the United States, 2014-18
SAM159	Novel Psychoactive Substances in Custodial Settings: A Mixed Method Investigation on the Experiences of People in Prison and Professionals Working With Them
SAM160	Genomics and epigenomics of addiction*
SAM161	A safe level of alcohol consumption: the right answer demands the right question
SAM162	Awareness of Alcohol as a Carcinogen and Support for Alcohol Control Policies
SAM163	Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation*
SAM164	Intelligence quotient decline following frequent or dependent cannabis use in youth: a systematic review and meta-analysis of longitudinal studies
SAM165	Evidence-Based Treatment of Young Adults With Substance Use Disorders
SAM166	Stigma and substance use disorders: A clinical, research, and advocacy agenda
SAM167	Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US
SAM92:2023-2026	Changes in Alcohol Use after Metabolic and Bariatric Surgery: Predictors and Mechanisms
SAM93:2023-2026	A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy
SAM94:2023-2026	A Novel Approach to Assessing Infants with Neonatal Abstinence Syndrome*
SAM95:2023-2026	Ultrarestrictive Opioid Prescription Protocol for Pain Management After Gynecologic and Abdominal Surgery
SAM96:2023-2026	Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study
SAM97:2023-2026	Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy
SAM98:2023-2026	Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice
SAM99:2023-2026	Association of E-Cigarette Use With Respiratory Disease Among Adults: A Longitudinal Analysis
SAM100:2023-2026	Gabapentin for the treatment of alcohol use disorder

SAM #	SAM Title - Journal Article
SAM101:2023-2026	Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial
SAM102:2023-2026	Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals with Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial
SAM103:2023-2026	Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?
SAM104:2023-2026	Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories
SAM105:2023-2026	Association Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016
SAM106:2023-2026	Association between medical cannabis laws and opioid overdose mortality has reversed over time
SAM107:2023-2026	Substance Use Stigma and Antiretroviral Therapy Adherence Among a Drug-Using Population Living with HIV
SAM108:2023-2026	Initiating buprenorphine treatment for opioid use disorder during short-term in-patient 'detoxification': a randomized clinical trial*
SAM109:2023-2026	Cannabis Use Based on Urine Drug Screens in Pregnancy and Its Association With Infant Birth Weight*
SAM110:2023-2026	Adding an orange to the banana bag: vitamin C deficiency is common in alcohol use disorders
SAM111:2023-2026	Youth and the Opioid Epidemic
SAM168	A comparison of acute pain management strategies after cesarean delivery
SAM169	Discontinuing Methadone and Buprenorphine: A Review and Clinical Challenges
SAM170	Retrospective Review of Need for Delayed Naloxone or Oxygen in Emergency Department Patients Receiving Naloxone for Heroin Reversal*
SAM171	Combining behavioural harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial
SAM172	Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial
SAM173	Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy
SAM174	Stigmatization of Pregnant Individuals with Opioid Use Disorder
SAM175	Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs*
SAM176	How Patient Centered Are Addiction Treatment Intake Processes?*
SAM178	Implementation of oral and extended-release naltrexone for the treatment of emergency department patients with moderate to severe alcohol use disorder: Feasibility and initial outcomes*
SAM179	Evaluation of Early vs Standard Liver Transplant for Alcohol-Associated Liver Disease
SAM180	Effect of Combination Treatment With Varenicline and Nicotine Patch on Smoking Cessation Among Smokers Who Drink Heavily: A Randomized Clinical Trial
SAM181	Effect of Incentives for Alcohol Abstinence in Partnership with 3 American Indian or Alaska Native Communities: A Randomized Clinical Trial.
SAM182	Multiple comparison of different noninvasive brain stimulation and pharmacologic interventions in patients with methamphetamine use disorders: A network meta-analysis of randomized controlled trials
SAM183	Young Adult Substance use and Healthcare Use Associated with Screening, Brief Intervention and Referral to Treatment in Pediatric Primary Care

SAM #	SAM Title - Journal Article
SAM184	Buprenorphine uptake during pregnancy following the 2017 guidelines update on prenatal opioid use disorder
SAM185	A prospective, randomized trial of the effect of buprenorphine continuation versus dose reduction on pain control and post-operative opioid use\
SAM186	Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis*
SAM187	Long-term Risk of Overdose or Mental Health Crisis After Opioid Dose Tapering
SAM188	Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper
SAM189	Birth Outcomes of Neonates Exposed to Marijuana in Utero: A Systematic Review and Meta-analysis
SAM190	Prescribing the Buprenorphine Monoprodut for Adverse Effects of Buprenorphine-Naloxone*
SAM191	Discharges “Against Medical Advice” in Patients With Opioid-related Hospitalizations*
SAM192	Preventing Hospital Readmission for Patients With Comorbid Substance Use Disorder: A Randomized Trial*
SAM193	Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
SAM194	The rewarding effects of alcohol after bariatric surgery: do they change and are they associated with pharmacokinetic changes?
SAM195	Injecting drug use, the skin and vasculature
SAM196	Hepatitis C Virus Elimination in Methadone-treated Patients: Implementation of Hepatology Clinic in a Methadone Treatment Program*
SAM197	Kratom—Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review
SAM198	A Taxonomy of Hospital-Based Addiction Care Models: a Scoping Review and Key Informant Interviews
SAM199	Association of Recreational Cannabis Legalization With Alcohol Use Among Adults in the US, 2010 to 2019
SAM200	Microinduction of Buprenorphine/Naloxone: A Review of the Literature*
SAM201	Adverse Childhood Experiences and stimulant use disorders among adults in the United States
SAM202	Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review
SAM203	Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects
SAM204	Concurrent use of opioids and stimulants and risk of fatal overdose: A cohort study
SAM205	Association of cannabis potency with mental ill health and addiction: a systematic review*
SAM206	Treatment of Overdose in the Synthetic Opioid Era
SAM207	Increased risk of death immediately after discharge from compulsory care for substance abuse
SAM208	Xylazine and Overdoses: Trends, Concerns, and Recommendations*
SAM210	Gender differences in any alcohol screening and discussions with providers among older adults in the United States, 2015-2019
SAM211	Alcohol and the Brain: from Genes to Circuits
SAM212	The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
SAM213	Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails
SAM214	Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation
SAM215	A Review of the Metabolism and Potential Drug-drug Interactions With Addictive Drugs*
SAM216	Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?

SAM #	SAM Title - Journal Article
SAM217	Buprenorphine management in the Perioperative period: educational review and recommendations from a multi society expert panel
SAM218	Opioid Overdose in the Hospital Setting: A Systematic Review*
SAM219	A non-hallucinogenic psychedelic analogue with therapeutic potential
SAM220	Cocaethylene: When Cocaine and Alcohol Are Taken Together
SAM221	Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation
SAM112:2023-2026	Alcohol medical intervention clinic: A rapid access addiction medicine model reduces emergency department visits*
SAM113:2023-2026	Cannabis use disorder and the lungs*
SAM114:2023-2026	Change in the Relationship Between Drinking Alcohol and Risk of Violence Among Adolescents and Young Adults: A Nationally Representative Longitudinal Study
SAM115:2023-2026	Infectious diseases occurring in the context of substance use disorders: A concise review*
SAM116:2023-2026	Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study
SAM117:2023-2026	Barriers and Facilitators to Clinician Readiness to Provide Emergency Department-Initiated Buprenorphine
SAM118:2023-2026	Using Data to Guide Action in Response to the Public Health Crisis of Opioid Overdoses*
SAM119:2023-2026	Caffeine Restrictions in Inpatient Psychiatric Settings: Precipitating Withdrawal?*
SAM120:2023-2026	Effect of screening, brief intervention and referral to treatment for unhealthy alcohol and other drug use in mental health treatment settings: A randomized controlled trial
SAM121:2023-2026	rTMS-Induced Changes in Glutamatergic and Dopaminergic Systems: Relevance to Cocaine and Methamphetamine Use Disorders
SAM122:2023-2026	Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis
SAM123:2023-2026	Electronic and Combustible Cigarette Use in Adolescence: Links With Adjustment, Delinquency, and Other Substance Use
SAM124:2023-2026	Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine
SAM125:2023-2026	Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine
SAM126:2023-2026	Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?
SAM127:2023-2026	Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study
SAM128:2023-2026	Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study*